|
US3655679A
(en)
|
1969-06-25 |
1972-04-11 |
Merck & Co Inc |
Certain aryl pyridine carboxylic acid derivatives
|
|
US3703582A
(en)
|
1970-04-20 |
1972-11-21 |
Merck & Co Inc |
Aryl pyridine carboxylic acids in the treatment of inflammation
|
|
US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
|
CA1261335A
(en)
|
1984-08-29 |
1989-09-26 |
Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee |
Ethylenediamine monoamide derivatives
|
|
CN1023479C
(zh)
|
1985-09-27 |
1994-01-12 |
弗·哈夫曼-拉罗切有限公司 |
乙二胺的单酰胺衍生物的制备方法
|
|
TW219933B
(cg-RX-API-DMAC7.html)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
|
DE4219158A1
(de)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
|
DE59401923D1
(de)
|
1993-11-02 |
1997-04-10 |
Hoechst Ag |
Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
EP0650961B1
(de)
|
1993-11-02 |
1997-03-05 |
Hoechst Aktiengesellschaft |
Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
TW406076B
(en)
|
1993-12-30 |
2000-09-21 |
Hoechst Ag |
Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
|
|
DE4410423A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
DE4410480A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US5789426A
(en)
|
1995-01-20 |
1998-08-04 |
Cornell Research Foundation, Inc. |
Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
|
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
|
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
|
WO1997041103A1
(de)
|
1996-04-30 |
1997-11-06 |
Hoechst Aktiengesellschaft |
3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
|
|
DE19620041A1
(de)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhäsionsrezeptor-Antagonisten
|
|
DE19650215A1
(de)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
EP1024134A4
(en)
|
1997-10-09 |
2003-05-14 |
Ono Pharmaceutical Co |
DERIVATIVES OF AMINOBUTANIC ACID
|
|
DE19746287A1
(de)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
JP4495339B2
(ja)
|
1998-03-23 |
2010-07-07 |
アベンティス・ファーマスーティカルズ・インコーポレイテツド |
ピペリジニルおよびｎ−アミジノピペリジニル誘導体
|
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
|
JP2001048786A
(ja)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
三環式ヘテロアリール誘導体
|
|
DK1265608T3
(da)
|
2000-03-22 |
2008-12-08 |
Pharmacia & Upjohn Co Llc |
Oxazolidinon tabletformulering
|
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
|
JP4590157B2
(ja)
|
2001-03-21 |
2010-12-01 |
アイシス イノヴェイション リミテッド |
アッセイ、方法および手段
|
|
SE0101327D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
ES2686625T3
(es)
|
2001-12-06 |
2018-10-18 |
Fibrogen, Inc. |
Métodos para el tratamiento o prevención de la anemia
|
|
WO2003097040A1
(en)
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
|
AU2003265674B2
(en)
|
2002-08-29 |
2008-12-11 |
Merck & Co., Inc. |
N-biarylmethyl aminocycloalkanecarboxamide derivatives
|
|
EP1554394B1
(en)
|
2002-10-16 |
2009-12-16 |
Isis Innovation Limited |
Screening methods using a structural model of FIH
|
|
CA2506799A1
(en)
|
2002-11-21 |
2004-06-10 |
Eli Lilly And Company |
Mixed lineage kinase modulators
|
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
|
US7183287B2
(en)
|
2003-04-03 |
2007-02-27 |
Pharmacia Corporation |
Substituted pyrimidinones
|
|
US8614204B2
(en)
|
2003-06-06 |
2013-12-24 |
Fibrogen, Inc. |
Enhanced erythropoiesis and iron metabolism
|
|
KR100932169B1
(ko)
|
2003-06-06 |
2009-12-16 |
피브로겐, 인크. |
질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
|
|
US20060251638A1
(en)
|
2003-06-06 |
2006-11-09 |
Volkmar Guenzler-Pukall |
Cytoprotection through the use of hif hydroxylase inhibitors
|
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
|
JPWO2005108370A1
(ja)
|
2004-04-16 |
2008-03-21 |
味の素株式会社 |
ベンゼン化合物
|
|
ES2332798T3
(es)
|
2004-05-28 |
2010-02-12 |
Fibrogen, Inc. |
Ensayo de actividad de la prolil hidroxilasa de hif.
|
|
EP1771418A2
(en)
|
2004-05-31 |
2007-04-11 |
Tanabe Seiyaku Co., Ltd. |
Large conductance calcium-activated k channel opener
|
|
CA2573185A1
(en)
|
2004-07-14 |
2006-02-23 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis c
|
|
TW200616969A
(en)
|
2004-09-17 |
2006-06-01 |
Tanabe Seiyaku Co |
Imidazole compound
|
|
DE05815688T1
(de)
*
|
2005-01-27 |
2008-06-26 |
Alembic Ltd. |
Levetiracetam-formulierung mit verlängerter freisetzung
|
|
US20080213404A1
(en)
|
2005-02-04 |
2008-09-04 |
Johnson Randall S |
Hif Modulating Compounds and Methods of Use Thereof
|
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
|
CN101849943A
(zh)
|
2005-06-06 |
2010-10-06 |
菲布罗根公司 |
使用HIFα稳定剂的改进的贫血治疗
|
|
EP1919463B9
(en)
|
2005-06-15 |
2011-02-02 |
Fibrogen, Inc. |
Use of hif 1alfa modulators for treatment of cancer
|
|
WO2007033216A2
(en)
|
2005-09-12 |
2007-03-22 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
|
US20090176726A1
(en)
|
2005-10-11 |
2009-07-09 |
Fisher David E |
Methods for treating mitf-related disorders
|
|
US7728130B2
(en)
|
2005-12-09 |
2010-06-01 |
Amgen Inc. |
Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
|
|
GB2453819A
(en)
|
2006-01-09 |
2009-04-22 |
Btg Int Ltd |
Modulators of hypoxia inducible factor-1 and related uses
|
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
|
JP4801451B2
(ja)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
|
|
TW200738709A
(en)
|
2006-01-19 |
2007-10-16 |
Osi Pharm Inc |
Fused heterobicyclic kinase inhibitors
|
|
ITMI20060179A1
(it)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
|
|
US7625927B2
(en)
|
2006-02-27 |
2009-12-01 |
Alcon Research, Ltd. |
Method of treating glaucoma
|
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
|
AR059733A1
(es)
|
2006-03-07 |
2008-04-23 |
Smithkline Beecham Corp |
Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
|
|
ES2288117B1
(es)
|
2006-05-08 |
2008-12-01 |
Combino Pharm, S.L. |
Composicion farmaceutica solida de gabapentina.
|
|
US20090176825A1
(en)
|
2006-05-16 |
2009-07-09 |
Fitch Duke M |
Prolyl hydroxylase inhibitors
|
|
AR061570A1
(es)
|
2006-06-23 |
2008-09-03 |
Smithkline Beecham Corp |
Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
|
|
MX2009000286A
(es)
|
2006-06-26 |
2009-03-20 |
Procter & Gamble |
Inhibidores de prolil hidroxilasa y metodos de uso.
|
|
CL2008000066A1
(es)
|
2007-01-12 |
2008-08-01 |
Smithkline Beecham Corp |
Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
|
|
TW200845994A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: prolyl hydroxylase inhibitors
|
|
JP2008201711A
(ja)
*
|
2007-02-20 |
2008-09-04 |
Ss Pharmaceut Co Ltd |
システイン臭が低減された固形製剤
|
|
CN101663037A
(zh)
|
2007-04-18 |
2010-03-03 |
默克公司 |
新的1,8-二氮杂萘化合物
|
|
ES2446418T3
(es)
|
2007-04-18 |
2014-03-07 |
Amgen, Inc |
Derivados de indanona que inhiben la prolil hidroxilasa
|
|
ES2389063T3
(es)
|
2007-05-04 |
2012-10-22 |
Amgen, Inc |
Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
|
|
WO2008144266A1
(en)
|
2007-05-16 |
2008-11-27 |
Merck & Co., Inc. |
Spiroindalones
|
|
RU2009146851A
(ru)
|
2007-05-18 |
2011-06-27 |
Байер Шеринг Фарма Акциенгезельшафт (DE) |
Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
|
|
EP2186528B1
(en)
|
2007-08-06 |
2014-03-19 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
|
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
|
CN101815718A
(zh)
|
2007-08-10 |
2010-08-25 |
克里斯捷诺米有限公司 |
吡啶衍生物及其用法
|
|
WO2009035534A2
(en)
|
2007-09-07 |
2009-03-19 |
The Cleveland Clinic Foundation |
Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
|
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
|
AU2008331480A1
(en)
|
2007-11-30 |
2009-06-11 |
Glaxosmithkline Llc |
Prolyl hydroxylase inhibitors
|
|
EA201000920A1
(ru)
|
2007-11-30 |
2011-02-28 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Ингибиторы пролилгидроксилазы
|
|
US8269008B2
(en)
|
2007-12-03 |
2012-09-18 |
Fibrogen, Inc. |
Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
|
|
US20100298324A1
(en)
|
2007-12-19 |
2010-11-25 |
Smith Kline Beecham Corporation |
Prolyl Hydroxylase Inhibitors
|
|
WO2009086592A1
(en)
|
2008-01-04 |
2009-07-16 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
|
US8952160B2
(en)
|
2008-01-11 |
2015-02-10 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
|
|
JP5380465B2
(ja)
|
2008-03-03 |
2014-01-08 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Ｔｌｒ活性モジュレーターとしての化合物および組成物
|
|
WO2010010017A1
(en)
|
2008-07-23 |
2010-01-28 |
F. Hoffmann-La Roche Ag |
Heterocyclic antiviral compounds
|
|
NZ591394A
(en)
|
2008-09-15 |
2013-03-28 |
Kasina Laila Innova Pharmaceuticals Private Ltd |
Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
|
|
AU2009314155B2
(en)
|
2008-11-14 |
2015-10-08 |
Fibrogen, Inc. |
Thiochromene derivatives as HIF hydroxylase inhibitors
|
|
HRP20130846T1
(hr)
|
2009-03-31 |
2013-11-22 |
Kissei Pharmaceutical Co., Ltd. |
Derivati indolizina i njihova uporaba u medicinske svrhe
|
|
PL2496236T4
(pl)
|
2009-11-06 |
2015-11-30 |
Aerpio Therapeutics Inc |
Inhibitory hydroksylazy prolilowej
|
|
JO2978B1
(en)
|
2009-12-21 |
2016-03-15 |
ايلي ليلي اند كومباني |
MGLU2 aids
|
|
CN103429239A
(zh)
|
2011-01-13 |
2013-12-04 |
菲布罗根有限公司 |
增加网织红细胞血红蛋白含量的方法
|
|
CA2837560C
(en)
|
2011-06-06 |
2017-02-14 |
Akebia Therapeutics Inc. |
Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
|
|
NO2686520T3
(cg-RX-API-DMAC7.html)
|
2011-06-06 |
2018-03-17 |
|
|
|
US20130022974A1
(en)
|
2011-06-17 |
2013-01-24 |
The Regents Of The University Of Michigan |
Dna methylation profiles in cancer
|
|
US9206134B2
(en)
|
2011-07-22 |
2015-12-08 |
Beijing Betta Pharmaceuticals Co. Ltd. |
Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
|
|
US20140309256A1
(en)
|
2011-11-09 |
2014-10-16 |
Fibrogen, Inc. |
Therapeutic Method
|
|
JP2015537013A
(ja)
|
2012-11-19 |
2015-12-24 |
アサンタ・アー／エス |
速崩性錠剤
|
|
JP2016519684A
(ja)
*
|
2013-04-08 |
2016-07-07 |
デニス エム ブラウン |
準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
|
|
RS60464B1
(sr)
*
|
2013-06-06 |
2020-07-31 |
Fibrogen Inc |
Farmaceutske formulacije inhibitora hif hidroksilaze
|
|
PT3007695T
(pt)
*
|
2013-06-13 |
2024-03-07 |
Akebia Therapeutics Inc |
Composições e métodos para tratamento de anemia
|
|
RU2016109125A
(ru)
|
2013-08-16 |
2017-09-22 |
Огайо Стейт Инновейшн Фаундейшн |
Композиции и способы модуляции метилирования днк
|
|
AR099354A1
(es)
|
2013-11-15 |
2016-07-20 |
Akebia Therapeutics Inc |
Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
|
|
WO2015112831A1
(en)
|
2014-01-23 |
2015-07-30 |
Akebia Therapeutics, Inc. |
Compositions and methods for treating ocular diseases
|
|
US10617716B2
(en)
|
2014-12-16 |
2020-04-14 |
Urgo Us, Inc. |
Hypochlorous acid formulations and methods for treating skin conditions
|
|
CN107427503A
(zh)
|
2015-01-23 |
2017-12-01 |
阿克比治疗有限公司 |
2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
|
|
WO2016153996A1
(en)
|
2015-03-20 |
2016-09-29 |
Akebia Therapeutics, Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
|
CR20170450A
(es)
|
2015-04-01 |
2018-04-03 |
Akebia Therapeutics Inc |
Composiciones y métodos para el tratamiento de la anemia
|